Lovastatin

• CAT Number: A000507
• CAS Number: 75330-75-5
• Molecular Formula: C₂₄H₃₆O₅
• Molecular Weight: 404.54
• Purity: ≥95%
• Synonyms: MK-803; Mevinolin; 75330-75-5; Mevacor; Monacolin K; Lovalip
• Target: HMG-CoA Reductase
• Solubility: >20.2mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
• InChI: InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
• InChIKey: PCZOHLXUXFIOCF-BXMDZJJMSA-N
• SMILES: CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C

Lovastatin（Cat No.:A000507）is a widely used cholesterol-lowering medication and one of the first statins developed, derived from Aspergillus terreus. It works by inhibiting HMG-CoA reductase, the key enzyme in cholesterol synthesis, effectively lowering low-density lipoprotein (LDL) levels in the blood. Lovastatin is primarily prescribed to reduce the risk of cardiovascular diseases, such as heart attack and stroke, in patients with hypercholesterolemia. Its benefits extend to anti-inflammatory and antioxidant effects, and it is also studied for potential anti-cancer properties, showing promise in addressing cardiovascular health and beyond.

Reference

1: Nozu T, Miyagishi S, Kumei S, Nozu R, Takakusaki K, Okumura T. Lovastatin
inhibits visceral allodynia and increased colonic permeability induced by
lipopolysaccharide or repeated water avoidance stress in rats. Eur J Pharmacol.
2017 Oct 28;818:228-234. doi: 10.1016/j.ejphar.2017.10.056. [Epub ahead of print]
PubMed PMID: 29107672.

2: Chung L, Bey AL, Towers AJ, Cao X, Kim IH, Jiang YH. Lovastatin suppresses
hyperexcitability and seizure in Angelman syndrome model. Neurobiol Dis. 2017 Oct
31;110:12-19. doi: 10.1016/j.nbd.2017.10.016. [Epub ahead of print] PubMed PMID:
29097328.

3: Hubert S, Chadwick A, Wacher V, Coughlin O, Kokai-Kun J, Bristol A.
Development of a Modified-Release Formulation of Lovastatin Targeted to
Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation.
J Pharm Sci. 2017 Oct 6. pii: S0022-3549(17)30686-X. doi:
10.1016/j.xphs.2017.09.028. [Epub ahead of print] PubMed PMID: 28989013.

4: Leone G, Consumi M, Pepi S, Lamponi S, Bonechi C, Tamasi G, Donati A, Rossi C,
Magnani A. Alginate-gelatin formulation to modify lovastatin release profile from
red yeast rice for hypercholesterolemia therapy. Ther Deliv. 2017
Oct;8(10):843-854. doi: 10.4155/tde-2017-0025. PubMed PMID: 28944737.

5: Tricarico PM, Gratton R, Braga L, Celsi F, Crovella S. 25-Hydroxycholesterol
and inflammation in Lovastatin-deregulated mevalonate pathway. Int J Biochem Cell
Biol. 2017 Nov;92:26-33. doi: 10.1016/j.biocel.2017.09.007. Epub 2017 Sep 14.
PubMed PMID: 28918367.

6: Bhargavi SD, Praveen VK, Anil Kumar M, Savitha J. Comparative Study on Whole
Genome Sequences of Aspergillus terreus (Soil Fungus) and Diaporthe ampelina
(Endophytic Fungus) with Reference to Lovastatin Production. Curr Microbiol. 2017
Sep 6. doi: 10.1007/s00284-017-1353-4. [Epub ahead of print] PubMed PMID:
28879444.

7: Seenivasan A, Gummadi SN, Panda T. Comparison of the elution characteristics
of individual forms of lovastatin in both isocratic and gradient modes and
HPLC-PDA method development for pure and fermentation-derived lovastatin. Prep
Biochem Biotechnol. 2017 Oct 21;47(9):901-908. doi:
10.1080/10826068.2017.1365239. Epub 2017 Aug 17. PubMed PMID: 28816626.

8: Lin HP, Tu HP, Hsieh YP, Lee BS. Controlled release of lovastatin from
poly(lactic-co-glycolic acid) nanoparticles for direct pulp capping in rat teeth.
Int J Nanomedicine. 2017 Jul 31;12:5473-5485. doi: 10.2147/IJN.S138410.
eCollection 2017. PubMed PMID: 28814864; PubMed Central PMCID: PMC5546772.

9: Melendez QM, Wooten CJ, Lopez D. Atorvastatin and lovastatin, but not
pravastatin, increased cellular complex formation between PCSK9 and the LDL
receptor in human hepatocyte-like C3A cells. Biochem Biophys Res Commun. 2017 Oct
7;492(1):103-108. doi: 10.1016/j.bbrc.2017.08.026. Epub 2017 Aug 9. PubMed PMID:
28802576.

10: Ziegler V, Henninger C, Simiantonakis I, Buchholzer M, Ahmadian MR, Budach W,
Fritz G. Rho inhibition by lovastatin affects apoptosis and DSB repair of primary
human lung cells in vitro and lung tissue in vivo following fractionated
irradiation. Cell Death Dis. 2017 Aug 10;8(8):e2978. doi: 10.1038/cddis.2017.372.
PubMed PMID: 28796249; PubMed Central PMCID: PMC5596560.